It may seem like stating the obvious but for athletes of all skill levels, there is always room for improvement, and right now investors could have the opportunity to score big. An individual’s athletic ability is traditionally measured by their speed, strength, agility, and endurance. Rarely is one’s cognitive development taken into consideration with their capacity to perform.
Take, for example, a Major League Baseball player, standing at home plate, ferociously awaiting their home-run pitch. From the time the pitcher throws a 95-mph fastball until it gets to the plate is roughly 430 milliseconds. On average, it takes 150 milliseconds for a Major Leaguer to get their bat around, leaving tens of milliseconds on the middle to decree whether to swing or not.
If the batter manages to connect with the ball, it’s based on the player’s years in developing the processing speed and reaction time needed to hit that ball; both are factors of cognitive development. Cognitive assessment technology for professional athletic development represents a multi-billion dollar industry that is piping hot with investor opportunities. As athletes recognize a never-before-seen realm of competitive edge over their opponents, one company, in particular, has what it takes to get ahead of the ball and connect.
ESPN Says That This Is A True First! XSport Global, Inc. (XSPT) Knows The Future Of Peak Performance & Investors Could Score Big Points!
Every seasoned athlete knows that every sport, be it basketball or golf, is ultimately a test of cognition. When we watch NBA players like Lebron James hit a game-winning 3-pointer or professional golfers like Tiger Woods putt their way to a PGA trophy, rarely do we consider their mental toughness and ability to perform under stress.
Enter XSport Global, Inc. (XSPT). This company is leading the cognitive assessment technology industry as they seek to further the success of high-performance athletes around the world through “leading sciences, innovative technologies, and pioneering digital media.”
The opportunity that XSport (XSPT) presents right now could be unparalleled as the market is wide open for this technology to take hold. Keep in mind that all of this is happening while XSport is showing no signs of slowing down. In September 2017, XSport (XSPT) strategically acquired Head Trainer, Inc; an innovative tech company focused on improving cognitive functioning for high-performance athletes through the use of their user-friendly mobile applications.
ESPN Senior Writer, Darren Rovell said[i] the HeadTrainer app “is the first sports-based app and offers to train the brain in the areas of focus and concentration, visual and spatial awareness, processing speed, memory, and decision-making.”
But unlike other sports technology and app development companies, HeadTrainer already has a laundry list of athletes endorsing the technology! Philadelphia Phillies outfielder Jose Bautista, golfer Rickie Fowler, racecar driver Dale Earnhardt Jr., football player Richard Sherman, and soccer player Alex Morgan, among others, are endorsing the new tool.
“Everyone is looking for that edge there’s only so far you can go with talent and your physical traits…The mental part of the game is the hardest to explain because you can feel it and, the sense was that until now you couldn’t practice it like having pitches thrown to you or fielding fly balls.”
– Jose Bautista, Philadelphia Phillies
Brain Training Is Important, And Investors Should Pay Attention Now
XSport (XSPT), through the acquisition of Head Trainer, Inc. and their powerful mobile app, is creating an opportunity for athletes around the world to reach their full potential and take rise above the competition in their sports.
As the awareness of brain fitness rises among individuals and professional athletes, the demand for cognitive development technology increases. According to their official website, the Head Trainer app is designed to “engage and improve cognitive skills in five key area: Focus/Concentration, Visual-Spatial Awareness, Decision Making, Memory and Processing Speed.”
Cognitive skills are the core skills that the brain uses to think, learn, and, in the case of sports, perform. If professional athletes want to strengthen their game, they need to strengthen their mind, and the Head Trainer App, backed by XSport, is the key to unlocking an athlete’s peak mental capacity.
According to a recent market research report[ii] published by cognitive assessment industry professionals, the global assessment and training market is set to grow from $1.98 billion in 2018 to $8.06 billion by 2021, at a “Compound Annual Growth Rate (CAGR) of 32.3%. Current cognitive training systems are generally designed for non-athletic training where a subject is in a calm, quiet environment. Along including traditional sight and touch cognitive training modules, XSport (XSPT), by contrast, is building its technology around replicating a true sporting event environment.
For instance, XSport (XSPT) can incorporate outside and background noise in future releases. By utilizing headphones with environment-specific, programmed noise, audio tracks, and prompts, the company has created its product with an integrated audio track, sight, touch, and sound training systems that allows the athlete to train in an environment that is similar to the actual competition. This fact alone could set XSport (XSPT) above and beyond its competition.
And the writing could already be on the wall for investors. The Brain Health Devices Market is expected to have a profoundly favorable outlook for the next five years 2018-2026 according to a recently released Brain Health Devices Market research report[iii]. Part of this growth is expected to be fueled by significant market developments like mergers and acquisitions. Big deals are already being struck.
For example, Vivity Labs Inc., the makers of Fit Brains Trainer, which offers a suite of brain-training exercises, was acquired by Rosetta Stone for $12 million[iv]. And though full details have not been disclosed, Hachette Livre, a company that delivered revenue of €2.289B in 2017, acquired a majority stake in Brainbow, which created its brain training application for non-sports based cognitive education[v].
The momentum is evident, and now XSport (XSPT) could be presenting a unique opportunity in the market specifically for cognitive function in sports applications.
Know Thy Self, Know Thy Enemy. A Thousand Battles, A Thousand Victories
Every coach worth their weight in wisdom knows that the key to beating the competition is extensive knowledge of their strengths and weaknesses. In one of their recent annual fiscal reports[vi], Head Trainer, Inc., indicated that they were well aware of several companies in the industry that have developed rudimentary versions of cognitive training platforms, but believe that their product is far superior.
XSport’s biggest rival in the cognitive assessment space is Cogstate Ltd a science and technology solutions company based in Australia. The company’s goal, according to their official site, is to “invest in enhanced solutions to meet the current and future needs of clinical trials in central nervous system indications.”
While this is admirable and will benefit approaches to cognitive medicine, Cogstate’s short-sighted vision comes nowhere close to rapidly growing industry surrounding the application of cognitive assessment for athletes. This narrow focus seeks to “simplify the measurement of cognition,” and nothing else.
Market analysts looking at the cognitive assessment market should take this as an indication that there may be nothing standing in the way of XSport’s (XSPT) dominance over the sector. Don’t just limit the company to its strategic investment in the improvement of athletic mental performance either.
XSport (XSPT) Strategically Advances Into Corporate Holding Space Through Acquisition and Partnership with Shift Now, Inc.
Like any large market leader in their respective field, XSport (XSPT) is taking a strategic approach to the market and ensuring that it can handle a full-scale sports technology and media holding business. This is all while remaining focused on developing “disruptive sports-centric technologies and related media projects around the world.”
In early September 2018, XSport (XSPT) announced the acquisition of the Greensboro-based, brand agency, Shift Now, Inc., a “full-service creative and digital marketing” firm.
“With the acquisition of Shift Now, a profitable and scalable revenue generating firm, coupled with the outstanding team of professional employees Kristi Griggs has attracted, we now have our own leading agency to magnify our brands and transform the overall market. This highly complementary acquisition of Shift Now will serve as the foundation for XSport Global to develop our brands for the youth sports market without having to pay the high-margin, billable hours of outside creative agencies.” -Robert Finigan, CEO of XSport Global
The deal gives XSport (XSPT) round-the-clock access to innovative approaches to marketing and will allow for Head Trainer, Inc. and XSport’s other holdings to strategically reach market investors, and target desired audiences.
As XSport (XSPT) shifts their focus to building out their corporate holdings, the addition of Shift Now, Inc with more than $3 million in annual revenue, presents an opportunity that can be vertically integrated into their business model. With investment potential growing by the second, XSport is designing their corporate infrastructure to be scalable and adaptive to the needs of consumers and market investors alike.
XSport (XSPT): Built By A Leading Roster Of Industry Professionals
XSport (XSPT) has been built and is being led by a team driven by success. Dr. Brian Monteleone, a Charlotte-based sports psychologist, helped build the framework for HeadTrainer. During his 25 year career, Dr. Monteleone has worked in private practice, as a sports psychologist, Clinical Coordinator for an inpatient psychiatric and substance abuse hospitals, Clinical Director of a federally funded juvenile boot camp program, and counselor in a residential treatment center for dually-diagnosed adolescents.
In addition to Monteleone, Dr. Claude T. Moorman, III helped lead the charge to develop the specific sports-themed challenges that would be fun while also testing the brain’s vital cognitive areas. With the goal of getting people to recognize that cognition is a huge part of performance, the team designed a platform geared toward sharpening cognitive abilities specific to sports.
Once a team doctor for the Baltimore Ravens, Dr. Claude Moorman, also has a wealth of experience tending to athletes at the highest levels. Atrium Health, previously Carolinas HealthCare System, named Claude “T.” Moorman, III, MD as the new president of Atrium Health’s musculoskeletal institute and The Edward N. Hanley, Jr. Endowed Chair of the Department of Orthopedic Surgery.
Dr. Moorman also served as executive director of the James R. Urbanski Sports Sciences Institute at Duke University Medical Center, professor and vice chairman of the Department of Orthopedics and head team physician for Duke University Athletics.
Robert Finigan, XSport’s (XSPT) Chief Executive Officer, has a reputation in brand development that speaks for itself. Throughout his career, Finigan has served in various C-level roles for global companies in technology, health and Wellness and Media, in addition to several consulting and strategy firms, and has been recognized for many award-winning brand identity initiatives.
Robert also recognizes the importance of giving back to the community. In recent years, Finigan has served as President of the Heart and Soul Foundation; a 501(3)c focused on supporting and redefining music education. Finigan’s consumer and industry savvy, coupled with the vision of XSport, gives the company that competitive advantage that it needs to succeed.
Furthermore, Hank Durschlag is the Founder and Chairman of the Board of Directors of HeadTrainer, Inc. Mr. Durschlag previously served a President of Double Eagle Holdings, LLC, and as CEO of HealthSport, Inc., both R&D companies involved in the development of nutraceutical and other products for professional and amateur athletes. Hank was a founding partner and served as President of GlucoTec, Inc. (now Glytec Systems), a developer of FDA-approved software related to intravenous dosing of medications and other fluids.
Mr. Durschlag was also the Vice President of Sales & Marketing for Diabetes Management Services, Inc. (DMS), a national diabetes products and service company with treatment modules focusing on acute care, and women’s health. Hank received a Bachelor’s Degree from California University of Pennsylvania, California, PA, and a Master’s Degree in Business Administration from Clemson University, Clemson, SC.
Funds Give Vote Of Confidence To XSport (XSPT)
During the middle of the fourth quarter, XSport (XSPT) reached yet another major milestone in attracting notable backing from an up and coming fund. TRITON FUNDS was started by three undergraduate students from Southern California aspiring to create an investment fund with a millennial touch. In November, the Fund inked a deal with XSport (XSPT) to push up to another $1 million in development capital into the company. And in their own words, the leadership of TRITON appears to be more than happy to be able to get an early opportunity with this company:
“We continue to seek out the best investment opportunities and XSport Global represents the type of early-stage, growth company we intend to add to our portfolio of investments. We believe their business acumen and strategy is sound, and we are confident with the tremendous upside potential in the multi-billion dollar cognitive sports training industry. We look forward to working together.” – Yash Thukral, Founder of TRITON FUNDS.
“A management team that is highly motivated in seeing through the Company’s vision is something we here at TRITON FUNDS highly emphasize, and Robert Finigan provided just that for XSPT,” added Dmitriy Slobodskiy, Junior Partner, of TRITON FUNDS. “As a millennial fund, we pride ourselves in working with companies such as XSport Global who directly affect our generation as well as the youth in providing new technology and insight in an ever-changing space.”
The Game Has Only Just Begun
Old school agents and young reporters have recently shifted focus on what the next “Moneyball phenomena” will be. Mental, emotional, and health metrics are some of the common data points that these thinkers forecast will be part of the next sports analytical movement.
XSport (XSPT), backed by a roster of professional athletes and brand ambassadors, is leading the cognitive assessment industry to help athletes achieve their full potential. With HeadTrainer, Inc. and their mobile application, XSport (XSPT) can rise above the rest.
What separates HeadTrainer from other “brain-training” apps is not only the sports-themed user experience but the robust audio and video components – incorporating interactive messages and positive reinforcement from some of the top athletes in sports along with distractive sounds to help enhance the focus and concentration component of training.
“If I can process information faster and make decisions sooner, I can react quicker, and that can be the difference between a first down for my opponent or a pick-six for my team. The smart player wins.” – Richard Sherman, NFL Seattle Seahawks, San Francisco 49ers
With rapid advancements in technology, the adoption of cognitive assessment solutions is expected to result in massive market growth opportunities in the next five years. Because of the growing need for professional athletes to enhance their cognitive functions and annihilate their competition, this technology could build out its own niche within the sector.
The next big boom in the sports performance industry is technology designed to improve cognitive functions. Young athletes entering the professional levels of their sports are failing to recognize the importance of brain development. Factors like decision-making, processing speed, visual-spatial awareness, and reaction time will separate athletes from the pack, and XSport (XSPT) could lead athletes and investors to victory.
[ii] Market research report: https://www.marketsandmarkets.com/Market-Reports/cognitive-assessment-market-1039.html
[iii] Brain Health Research Report https://www.industrychronicle.com/brain-health-devices-market-exclusive-analysis-by-industry-recent-trends-size-and-forecast-up-to-2026/
[iv] Rosetta Stone acquires Vivity Labs https://www.fastcompany.com/3023881/rosetta-stone-buys-brain-training-app-seeks-to-expand-beyond-language-learning
[v] Hachette Livre acquisition of majority stake in Brainbow https://www.forbes.com/sites/ellenduffer/2016/12/31/hachette-livre-acquires-majority-stake-in-brainbow/
[vi] XSPT Financial report: https://www.sec.gov/Archives/edgar/data/1628104/000114036118014328/form10k.htm
DISCLAIMER: Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and XSport Global, Inc. we were hired for a period from 11/4/2018 – 2/4/2019 to publicly disseminate information about XSport Global, Inc. including on the Website and other media including Facebook and Twitter. We were paid $50,000 (CASH) for & were paid “0” shares of restricted common shares. We own zero shares of XSport Global, Inc., which we purchased in the open market. We may buy or sell additional shares of XSport Global, Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer
Stock Price Friday Update – November 8, 2019
Will Apple Inc.’s (AAPL) Stock Price Head Higher As Cord Cutting Continues?
Thanks to more attention from entertainment moguls, we’re seeing the advent of new services. These come from the likes of NBC, Disney, HBO and yes, Apple. Even with this being the case, the “cord-cutting” trend doesn’t appear to be slowing down anytime soon. What other companies are influenced by this trend?
3 Biotech Stocks to Watch Before Thanksgiving
Biotech is a sector that certainly turns a lot of head and has managed to create a lot of value for investors over the years. On that note, here is a look at three biotech stocks that should be watched closely by investors.
3 Defense Stocks to Watch in November
Over the years it has become abundantly clear that defense spending is going to rise every year and hence, defense stocks have naturally emerged as some of the safest investments in the market. However, the current unstable geopolitical situation in different corners of the world could lead to even more defense spending, if a Bank of America analyst is to be believed.
UBER stock in Focus Ahead of Q3 Earnings
Struggle To Profitability Continues
Uber Technologies Inc. (NYSE:UBER) stock has been on a downward spiral having lost 35% since its IPO. The company has continues to grapple to demonstrate a path to profitability and investors are pessimistic about the company. As a result, investors will be looking at the Q3 2019 earnings when the company reports its results on November 4.
Analysts expect Uber to post losses in Q3
When the company releases the results on Monday analysts expect the company to post an adjusted loss of $0.83 per share on revenue of $3.75 billion. This is however not surprising considering losses are common for tech companies in the growth phase. However, the major concern among investors is the lack of a clear strategy to turn the company into profitability.
The uncertainty about its path to profitability has led to the stock to continue bleeding. With the earnings report, the company should drive out the notion that its business is softening. When the company reported its Q2 earnings there was no assurance on the same with adjusted YoY revenue dropping 12%.
Uber CEO optimistic of about growth of the platform
Although the company is facing profitability challenges its CEO Dara Khosrowshahi holds a different view. Khosrowshahi is urging investors to concentrate on the capability of Uber’s evolving platform. He says that the platform will soon be part of the biggest transport ecosystem. This includes the fast-growing Uber Eats segment, Freight delivery, ride-sharing services electric scooter and driverless cars.
Uber’s latest addition to the expansion of its services is Cornershop. This is a service helping food retailers, pharmacies and supermarket chains to deliver their products. This is perhaps possible considering the tech company has revolutionized how people move around in major cities.
The company controls around 65% of the ride-sharing market in Europe, Latin America, Australia, and North America. However, there is growing competition from other emerging ride-sharing companies. Uber’s largest competitor is Lyft Inc. (NASDAQ: LYFT) which is almost turning a profit. On Wednesday Lyft released Q3 results that topped analyst forecasts.
3 Popular Biotech Stocks To Watch in November
Over the years, the biotech sector has been a bit of a gold mine when it comes to stocks and thousands of investors have been able to make significant profits by backing the right companies. The innovative solutions and technical advancements that have been brought into the sector by different companies is another factor behind the continued growth.
However, it needs to be mentioned that when it comes to investing in the right stock, an investor needs to conduct his research and watch the market closely. On that note, here is a look at three biotech stocks that could be tracked after their latest updates.
Pharmacyte Biotech (PMCB)
PharmaCyte announced today that its partner, Austrianova Singapore (Austrianova), has successfully completed the encapsulation of the cells from PharmaCyte’s Master Cell Bank in the second of two staggered and back-to-back manufacturing runs for the production of PharmaCyte’s clinical trial product. This product will be used for PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer (LAPC).
Why is this so pivotal for the company? Aside from getting one step closer to a confirmed IND submission, this shows that the company’s able to replicate its cell encapsulation process. It may not appear as a big deal on the surface but for those who know biotechnology, the whole process of bringing a successful treatment to market can hinge on the ability to duplicate it hundreds, if not thousands of times.
Here’s where it may get even more exciting. Company CEO Ken Waggoner said, “We are anxiously awaiting the completion of the second of the two back-to-back manufacturing runs and the results from the FDA required testing on each of those runs. Once the information from that testing is available, it will be incorporated into our Investigational New Drug application (IND) for submission to the FDA.”
“FOR SUBMISSION TO THE FDA,” once testing information is available. Obviously, with early-stage biotech, the proof is in the pudding. Right now Pharmacyte (PMCB) could be looking at its next milestone.
Tonix Pharmaceuticals (TNXP)
The first biotech stock to consider is that of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP), which made a major announcement with regards to its stock on Thursday. The clinical-stage biopharmaceutical biotech firm announced that its outstanding common stock is going to undergo a 1 to 10 reverse split. Traders need to note that the split will go into effect from November 1.
This particular move has been initiated by Tonix to possible ensure that the bid price of its stock does not go below the stipulated $1. The board of directors at Tonix had approved the reverse split of the stock and it remains to be seen how the stock moves over the coming days. This is a stock that should definitely be watched over the coming days.
CHF Solutions (CHFS)
The other biotech stock that is in the news today is that of CHF Solutions Inc (NASDAQ:CHFS). This morning the company announced that is going to change some aspects of its sales force in order to enhance its effectiveness.
The news resulted in a major rally in the stock and it has gained as much as 40% on Friday, after gaining as much as 106% earlier in session. The company stated in its press release that the focus of the sales force is going to be moved more towards its pediatrics and cardiac surgery products. The clearance of a 510(K) by the FDA is expected to come through soon and once that happens, the changeover will go into effect.
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Featured2 weeks ago
3 Biotech Stocks to Watch Before Thanksgiving
Biotechnology1 week ago
3 Biotech Stocks to Watch After Key, 4th Quarter Developments
Biotechnology1 week ago
Biotech Stocks To Watch This Week
Biotechnology2 weeks ago
3 Biotech Stocks To Watch Now After Big Market News
Biotechnology3 days ago
PharmaCyte Biotech (PMCB) Successfully Completes Final Manufacturing Run of Clinical Trial Product
Featured1 week ago
3 Biotechnology Stocks To Know Before 2020
Biotechnology2 days ago
The Biotech Index Just Hit New Highs; Stocks To Watch
Biotechnology7 days ago
3 Biotech Stocks To Watch As The Sector Heats Up